Kate Atkin
Associate Director Immunocore
Kate Atkin, PhD, is Associate Director of Antibody Platform in the Protein Engineering department at Immunocore, leading antibody engineering efforts for innovative T-cell engager platforms. In her 11 years at Immunocore, Kate has led teams through multiple pHLA-targeting preclinical programs in Oncology and Infectious Diseases. At the Summit, she will present on “A TCR and TCR-mimetic discovery platform for targeting diverse peptide-HLA complexes”.
Seminars
Wednesday 10th December 2025
Leveraging TCR-Based & TCR-Mimetic Bispecifics to Overcome Specificity & Density Challenges in Solid Tumours
11:00 am
- Unlocking high tumour specificity with TCR-based bispecifics – exploring how targeting peptide–HLA complexes enables precision beyond surface tumourassociated antigens (TAAs), while addressing the challenge of low epitope density
- Understanding the expression threshold – evaluating how TCR affinity and antigen presentation levels impact engagement, efficacy, and safety, with learnings from TCRengineered therapies like tebentafusp
- Pushing beyond monoclonal limits – discussing the role of TCR-mimetics and dualtargeting strategies to improve on-target precision, reduce off-tumour effects, and broaden addressable patient populations
